HC Wainwright Forecasts Increased Earnings for Nanobiotix

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Stock analysts at HC Wainwright increased their FY2030 earnings per share (EPS) estimates for shares of Nanobiotix in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $2.95 for the year, up from their prior forecast of $2.65. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Nanobiotix’s current full-year earnings is $0.53 per share.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million during the quarter.

A number of other analysts have also commented on NBTX. Guggenheim lifted their target price on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, UBS Group lifted their target price on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Stock Down 3.9%

NBTX stock opened at $49.48 on Tuesday. Nanobiotix has a twelve month low of $3.64 and a twelve month high of $57.14. The business has a 50 day moving average of $35.36 and a 200 day moving average of $27.04.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently modified their holdings of NBTX. Optiver Holding B.V. purchased a new position in shares of Nanobiotix in the 3rd quarter worth $101,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix in the 4th quarter worth $220,000. Royal Bank of Canada boosted its stake in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Nanobiotix during the fourth quarter valued at $390,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.